论文部分内容阅读
目的 探讨Ⅰ期乳腺癌患者淋巴结、骨髓微小转移癌 (LNM、BMM )与临床预后因素的关系。方法 分别以抗上皮细胞膜单克隆抗体为探针 ,对 5 2例Ⅰ期乳癌中LNM ,BMM进行研究。结果 分别有 2 3%( 12 / 5 2 ) ,19.2 %( 10 / 5 2 )病例伴有LNM、BMM。在低分化乳癌组中 ,LNM( 4 5 .0 %,9/ 2 0 )或BMM( 35 .0 %,7/ 2 0 )阳性率明显高于高分化组 ( 9.3%,3/32 ;9.3%,3/ 32 ) (P <0 .0 1;<0 .0 5 )。在LNM阳性组中 ,BMM阳性率 ( 5 8.3%,7/ 12 )明显高于阴性组 ( 7.5 %,3/ 40 ) (P <0 .0 1)。结论 采用免疫组织化学技术可大大提高乳癌微小转移检出率 ,乳癌淋巴道 ,血道转移可同时发生。
Objective To investigate the relationship between lymph node, bone marrow micrometastasis (LNM, BMM) and clinical prognosis in patients with stage Ⅰ breast cancer. Methods Using monoclonal antibodies against epithelial cell membrane as probes, LNM and BMM in 52 cases of stage Ⅰ breast cancer were studied. The results were 23% (12/52), 19.2% (10/52) cases with LNM, BMM. The positive rate of LNM (45.0%, 9/20) or BMM (35.0%, 7/20) in poorly differentiated breast cancer group was significantly higher than that in well differentiated group (9.3%, 3/32; 9.3 %, 3/32) (P <0. 01; <0 .0 5). In LNM positive group, the positive rate of BMM (53.3%, 7/12) was significantly higher than that in negative group (7.5%, 3/40) (P <0.01). Conclusion Immunohistochemical techniques can greatly improve the detection rate of breast cancer micrometastasis, lymph node metastasis of breast cancer, hematogenous metastasis can occur simultaneously.